Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Non-Valvular Atrial Fibrillation
- 1 March 2006
- journal article
- research article
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 21 (4), 279-293
- https://doi.org/10.1159/000091265
Abstract
Background: To show results of a prespecified pooled analysis of the studies SPORTIF III (open-label) and SPORTIF V (double-blind), to assess the homogeneity of the results and to explore subgroup analyses and adverse events. Methods and Results: 7,329 patients with atrial fibrillation (AF) and ≧1 additional stroke risk factor were randomized to warfarin (international normalized ratio 2.0–3.0) or ximelagatran (36 mg twice daily). Over 11,346 patient-years (mean 18.5 months/patient), 184 patients developed primary events of stroke and systemic embolism (ximelagatran 1.62 vs. warfarin 1.65%/year; p = 0.94). Heterogeneity between trials with respect to the primary event rate (study-by-treatment interaction p = 0.026) was found. This could not be explained statistically by baseline patient characteristics or by treatment (except perhaps by the better anticoagulation with warfarin in SPORTIF V) and was not evident for secondary end-points. There was no conclusive difference in major bleeding rates (ximelagatran 1.88 vs. warfarin 2.46%/year; p = 0.054), but combined minor plus major bleeding was lower with ximelagatran (31.7 vs. 38.7%/year; p < 0.0001). Elevation of liver enzymes occurred more frequently in patients taking ximelagatran (6.1% vs. warfarin 0.8%; p < 0.0001) and was reversible except in rare cases. Conclusions: Fixed-dose oral ximelagatran without coagulation monitoring prevented stroke and systemic embolism as effectively as warfarin in patients with AF. Differences in the results of the two trials might relate to consistency of warfarin anticoagulation, different degree of blinding in the two trials, other concomitant therapies or chance. Further investigation is required to explore the long-term safety profile of ximelagatran.Keywords
This publication has 26 references indexed in Scilit:
- Hepatic Findings in Long-Term Clinical Trials of XimelagatranDrug Safety, 2005
- Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee ReplacementThe New England Journal of Medicine, 2003
- Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)American Heart Journal, 2003
- Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to qualityAmerican Heart Journal, 2003
- No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor XimelagatranClinical Pharmacokinetics, 2003
- No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male VolunteersClinical Pharmacokinetics, 2003
- Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug InteractionsClinical Pharmacokinetics, 2003
- Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin InhibitorClinical Pharmacokinetics, 2003
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke, 1988
- The Barthel ADL Index: A reliability studyInternational Disability Studies, 1988